Related Experiment Videos
Preclinical studies of antitumor prostaglandins by using human ovarian cancer cells
1Department of Obstetrics and Gynecology, National Defense Medical College, Saitama, Japan.
Abstract:
Pleiotropic actions of antitumor prostaglandins (PGs) on tumor cells are reviewed including our preclinical results focused on human ovarian cancer. Regarding inhibition of cell proliferation, antitumor PGs exerts its action as a G1 blocking agent. The cyclopentenone PGs inhibit myc oncogene expression while inhibiting the cell cycle progression and results in apoptotic cell death and growth inhibition. Cyclopentenone PGs inhibit growth of various tumors transplanted to mice or nude mice and show adjuvant effects to cis-diamminedichloroplatinum(II) (CDDP). In order to elucidate a role of antitumor PGs in immune systems, relevance of effects on tumor growth with those on the immune systems are also discussed with our results.
Insights
Antitumor prostaglandins (PGs) inhibit cancer cell proliferation by blocking the cell cycle and inducing apoptosis. Cyclopentenone PGs show efficacy against various tumors and enhance chemotherapy, with potential immune system roles discussed.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Prostaglandins (PGs) exhibit pleiotropic effects on tumor cells.
- Antitumor PGs, particularly cyclopentenone PGs, are investigated for their therapeutic potential.
- Ovarian cancer is a focus for preclinical studies on PG actions.
Purpose of the Study:
- To review the antitumorigenic actions of prostaglandins on tumor cells.
- To present preclinical findings on the effects of PGs in human ovarian cancer.
- To explore the role of antitumor PGs in modulating immune system responses relevant to tumor growth.
Main Methods:
- Review of preclinical data on prostaglandin actions.
- Analysis of G1 cell cycle blocking mechanisms.
- Investigation of myc oncogene expression inhibition.
- Xenograft studies in mice to assess tumor growth inhibition.
- Evaluation of adjuvant effects with cisplatin (CDDP).
Main Results:
- Antitumor PGs act as G1 blocking agents, inhibiting cell proliferation.
- Cyclopentenone PGs induce apoptosis and inhibit growth by suppressing myc oncogene expression.
- Cyclopentenone PGs demonstrate efficacy against transplanted tumors in vivo.
- Significant adjuvant effects were observed when combined with CDDP.
- The study discusses the interplay between PG effects on tumor growth and immune system modulation.
Conclusions:
- Antitumor prostaglandins, especially cyclopentenone PGs, possess significant anticancer properties.
- These PGs inhibit tumor cell proliferation, induce apoptosis, and enhance chemotherapy efficacy.
- Further research is warranted to fully elucidate the immunomodulatory roles of antitumor PGs in cancer therapy.